Texas Cardiac Arrhythmia Institute at St. David#s Medical Center to host EPLive 2018

Food and Healthcare Press Releases Monday February 26, 2018 10:08
AUSTIN, Texas--26 Feb--PRNewswire/InfoQuest
Two-day conference draws cardiac electrophysiology experts from across the globe

On March 1 and 2, 2018, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its fourth international symposium on complex arrhythmias, EPLive 2018. EPLive is an intensive, two-day educational meeting for practicing clinical cardiac electrophysiologists, electrophysiologist fellows and general cardiologists who have an interest in treating complex arrhythmias, a condition in which the heart beats with an irregular or abnormal rhythm. The primary teaching tool is live cases broadcast from the state-of-the-art laboratories at St. David's Medical Center, with expert commentary.

"This event draws leaders in the field of electrophysiology from across the globe," Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI and EPLive course director, said. "We are committed to advancing electrophysiology care, and this event gives us the opportunity to shape physician practices and expand the scope of electrophysiology treatment options available to all patients."

Arrhythmias are caused by problems with the heart's electrical system. Many cardiac arrhythmias are treated using modern ablation procedures, which involve burning, freezing or neutralizing portions of the heart muscle where abnormal electrical pulses set off the irregular heartbeats. EPLive is designed to help attendees gain a better understanding of techniques used to treat atrial and ventricular arrhythmias, implant complex devices and extract malfunctioning devices.

EPLive consists of four sections: Atrial Fibrillation (A Fib) ablation, Ventricular Tachycardia (VT) ablation, Devices and New Technology. The sessions consist of a combination of live and recorded cases from some of the world's premier centers: TCAI, Mayo Clinic, Stanford University Medical Center, Mount Sinai Hospital, UCLA Health System, the University of Pennsylvania Health System, University of Texas Southwestern Medical Center, University of Colorado Hospital, Vanderbilt Heart and Vascular Institute, Lancaster General Hospital and Massachusetts General Hospital.

Cases include procedures such as A Fib ablation, ventricular tachycardia (VT) ablation, epicardial and endocardial VT ablation, left atrial appendage closures, lead extraction and venoplasty. EPLive will also feature new technology pioneered by physicians at TCAI.

The conference will also focus on a variety of objectives, including:
  • Evaluating techniques used to map and ablate atrial and ventricular arrhythmias
  • Identifying processes to reduce complications and promote safety measures for the patient during ablation of A Fib and ventricular arrhythmias
  • Applying interventional approaches learned in ablation of complex ventricular arrhythmias
  • Demonstrating an understanding of the latest evidence and guidelines in arrhythmia management and treatment with new technology
  • Applying interventional approaches that best utilize the new technologies demonstrated to maximize clinical outcomes.

In addition to demonstrations by Dr. Natale, EPLive will feature presentations by a number of TCAI physicians, including course co-director, Amin Al-Ahmad, M.D., as well as Rodney Horton, M.D.; Patrick Hranitzky, M.D.; Robert Canby, M.D.; Joseph Gallinghouse, M.D.; Shane Bailey, M.D.; Javier Sanchez, M.D.; David Burkhardt, M.D., Jason Zagrodsky, M.D., and Luigi DiBiase, M.D.

Physicians will receive a maximum of 18 American Medical Association (AMA) Physician's Recognition Award (PRA) Category 1 Credit(TM) hours at the conference.

The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center is one of the world's preeminent centers dedicated to the latest treatment advances for correcting arrhythmias. The center is led by Dr. Natale, who is at the forefront of advancing treatment for A Fib, leading numerous clinical trials, and participating in the development of new technologies and procedures.

For more information, visit EPLiveSymposium.com.

Latest Press Release

The Menarini Group Announces Meropenem/vaborbactam European Marketing Authorization

- Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections - The first combination of a carbapenem and a beta-lactamase inhibitor approved for clinical use in...

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

- FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of first clinical data in BTC - BTC is a group of rare, aggressive...

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles - Evaluation to include...

Vitality-linked Insurers to Get 100 million People 20% More Active by 2025

Building on the results of the largest behaviour change study on physical activity, Vitality and its global network of insurers have collectively committed to improving the health of millions over the next seven years. This is in line with the World...

World Congress of Cardiology Cardiovascular Health 2018 Opens in Dubai

- Professor David Wood, President of the World Heart Federation, welcomes more than 5000 cardiologists, doctors, nurses, and health and policy experts from around the world to Dubai for WCC 2018 at a time when the opportunities for a sustainable impact...

Related Topics